The Effect of Lixisenatide on the Effect of Pituitary Hormones
- Status
- UnknownResults none
- Why it is watched
- non-weight indication: endocrine
- Who it enrolls
- age 18 Years to 60 Years; male; healthy volunteers accepted; no BMI minimum stated; conditions: Healthy; Type 1 Diabetes
- Interventions
- Placebo; Lixisenatide 10 micrograms (50 micrograms/ml in 3 ml) Pen Injector
- Conditions
- Healthy; Type 1 Diabetes
- Phase and size
- Phase 4 · 10 participants
- Dates
- Start 2023-04-17
Primary completion 2023-10-31 - Sponsor
- University of Tartu (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Growth hormone area under the curve.0-150 minutes after study drug administration
02Eligibility
Who can take part
Inclusion Criteria: 1. Healthy volunteers: * male sex * age 18-60 years * body weight \> 65 kg 2. Patients with type 1 diabetes: * type 1 diabetes * male sex * age 18-60 years * body weight \> 65 kg * c-peptide in fasting blood sample \<0,1 nmol/l * HbA1c \< 8,5% Exclusion Criteria: 1. Healthy volunteers: * use of aldosterone antagonist * use of glucocorticosteroid * use of other medication that potentially significantly affects pituitary function. 2. Patients with type 1 diabetes: * use of aldosterone antagonist * use of glucocorticosteroid * use of other medication that potentially significantly affects pituitary function. * The patient is excluded from the study if a significant change in blood glucose occurs in the study center.
03Change log
Registry changes
No changes recorded since the trial was added.